Berenberg analyst Caroline Palomeque resumed coverage of Cerevel Therapeutics with a Hold rating and $22 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics to participate in a conference call with H.C. Wainwright
- Cerevel Therapeutics price target lowered to $26 from $28 at Mizuho
- Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
- Cerevel Therapeutics price target lowered to $45 from $48 at H.C. Wainwright
- Wells Fargo downgrades Cerevel on lack of catalysts until 2024